



## Clinical trial results:

**Randomized phase II trial with irinotecan as monotherapy compared to irinotecan and bevacizumab (Bevlri) for patients with platinum resistant non-resectable esophagus-, cardia or gastric cancer**

### Summary

EudraCT number	2012-002321-30
Trial protocol	DK
Global end of trial date	02 May 2016

### Results information

Result version number	v1 (current)
This version publication date	14 March 2021
First version publication date	14 March 2021

### Trial information

#### Trial identification

Sponsor protocol code	12.01
-----------------------	-------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Odense University Hospital
Sponsor organisation address	J. B. Winsløws Vej 2, entrance 140, basement, Odense C, Denmark, 5000
Public contact	Ida Coordt Elle, Odense University Hospital, +45 29335922, ida.coordt.elle@rsyd.dk
Scientific contact	Per Pfeiffer, Odense University Hospital, +45 26283844, per.pfeiffer@rsyd.dk

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	01 March 2017
Is this the analysis of the primary completion data?	No

---

Global end of trial reached?	Yes
Global end of trial date	02 May 2016
Was the trial ended prematurely?	No

---

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To evaluate the efficacy of bevacizumab and irinotecan in combination compared to irinotecan alone in patients with esophagus, cardia or gastric cancer.

Protection of trial subjects:

Administration of pre-medication to minimize expected adverse events.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 September 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

---

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

---

Country: Number of subjects enrolled	Denmark: 50
Worldwide total number of subjects	50
EEA total number of subjects	50

---

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	26
From 65 to 84 years	24
85 years and over	0

---

## Subject disposition

### Recruitment

Recruitment details:

24 months starting September 2012.

### Pre-assignment

Screening details:

Patients with locally advanced or metastasizing ECV cancer after progression on first line treatment with platinum-based therapy.

### Period 1

Period 1 title	Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Arm B: Irinotecan+Bevacizumab
------------------	-------------------------------

Arm description:

Irinotecan + Bevacizumab

Arm type	Experimental
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

5 mg/kg i.v. infusion over 10 minutes on day 1 every other week.

Investigational medicinal product name	Irinotecan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution and suspension for suspension for injection in pre-filled syringe
Routes of administration	Intravenous use

Dosage and administration details:

180 mg/m<sup>2</sup> i.v. infusion over 30 minutes on day 1 every two weeks.

<b>Arm title</b>	Arm A: Irinotecan
------------------	-------------------

Arm description:

Irinotecan 180 mg/m<sup>2</sup> i.v. infusion over 30 minutes on day 1 every two weeks.

Arm type	Active comparator
Investigational medicinal product name	Irinotecan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

180 mg/m<sup>2</sup> i.v. over 30 minutes on day 1 every two weeks.

Number of subjects in period 1	Arm B: Irinotecan+Bevacizumab	Arm A: Irinotecan
Started	41	9
Completed	41	9

## Baseline characteristics

### Reporting groups

Reporting group title	Trial
-----------------------	-------

Reporting group description: -

Reporting group values	Trial	Total	
Number of subjects	50	50	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	26	26	
From 65-84 years	24	24	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	13	13	
Male	37	37	

### Subject analysis sets

Subject analysis set title	Patients
----------------------------	----------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

All patients in the trial.

Reporting group values	Patients		
Number of subjects	50		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	26		
From 65-84 years	24		
85 years and over	0		

Gender categorical			
Units: Subjects			
Female	13		
Male	37		

## End points

### End points reporting groups

Reporting group title	Arm B: Irinotecan+Bevacizumab
Reporting group description:	
Irinotecan + Bevacizumab	
Reporting group title	Arm A: Irinotecan
Reporting group description:	
Irinotecan 180 mg/m <sup>2</sup> i.v. infusion over 30 minutes on day 1 every two weeks.	
Subject analysis set title	Patients
Subject analysis set type	Full analysis
Subject analysis set description:	
All patients in the trial.	

### Primary: Progression-free survival

End point title	Progression-free survival <sup>[1]</sup>
End point description:	
End point type	Primary
End point timeframe:	
24 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The results of this trial were never fully analyzed.

Analysis is not available.

End point values	Arm B: Irinotecan+Bev acizumab	Arm A: Irinotecan	Patients	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	41	9	50	
Units: months				
median (confidence interval 95%)	4.5 (0 to 11)	5 (0 to 12)	5 (0 to 12)	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Last treatment + 30 days

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

### Reporting groups

Reporting group title	Patients
-----------------------	----------

Reporting group description: -

Serious adverse events	Patients		
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 50 (18.00%)		
number of deaths (all causes)	15		
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
Fracture			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Syncope			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General physical condition			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		



Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Dysphagia			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	2 / 50 (4.00%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Hydronephrosis			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Patients		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 50 (50.00%)		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	14 / 50 (28.00%)		
occurrences (all)	14		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	11 / 50 (22.00%)		
occurrences (all)	11		
Nausea			

subjects affected / exposed	6 / 50 (12.00%)		
occurrences (all)	6		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported